Interestingly, as has been shown in a recent study, the diagnostic accuracy to differentiate TP from PSP in WHO grade II-IV glioma may be dependent upon IDH mutation status with higher accuracies observed in the IDH-wildtype glioma group [16]. This evidence concerns the gene IDH1 and central nervous system cancer.